HK2 and colitis: Building upon previous findings from murine models that inhibition of HK2 expression either genetically or via the microbial metabolite butyrate protect from experimental colitis [6], these new data now show that indeed HK2 expression is dysregulated in the mucosa of patients with active inflammation and therefore suggest that targeting HK2 may represent a promising approach to suppress intestinal inflammation in humans.